Huntington's Gene Therapy Shows Slowing but Misses Significance at Four Years
Four-year data from a phase 1/2 trial of the gene therapy AMT-130 showed a 44 percent slowing of disease progression in high-dose Huntington's patients, but the result was not statistically significant. The Dutch company uniQure says the findings still indicate meaningful benefit and has reapplied for accelerated FDA approval. Huntington's disease is caused by expanded CAG repeats in the HTT gene, which produce a harmful protein and progressive neurodegeneration.
AMT-130 is an experimental one-time microRNA therapy intended to reduce mutant huntingtin protein. Huntington's arises from extra CAG repeats in HTT, producing a toxic protein and progressive nerve cell loss. The phase 1/2 program compared treated patients with matched controls; updated 48-month findings covered 12 high-dose recipients and showed a 44% slowing that did not meet statistical significance.
Earlier 36-month data, including three additional high-dose patients (15 total), found significant slowing: 80% on cUHDRS and 67% on TFC. uniQure attributed the weaker four-year primary result partly to survivorship bias, since more than half of matched control data was missing and faster-declining controls may have left follow-up.
For Huntington's families and clinicians, these mixed findings could sustain cautious hope while reinforcing uncertainty about how much the therapy alters long-term decline. Because treatment options remain limited, a regulatory decision may matter greatly to patients seeking access, though the lack of four-year statistical significance could complicate how benefits are described. Researchers and regulators may weigh the earlier significant 36-month signals against possible bias in the four-year comparison, shaping how future gene therapies for neurodegenerative disease are evaluated.